Stimuli‐Responsive Aptamer‐Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release
Advanced Healthcare Materials · 2024-09 · 13 (23)
DOI: 10.1002/adhm.202401020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 19.05.2024. Verfasst von Shanshan Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory of Biomedical Information Engineering of Ministry of Education, Xi'an Jiaotong University, Xi'an, 710049, P. R. China. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Delayed-Action Preparations, Drug Delivery Systems. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China, "SanQin Scholar" Innovation Team of Shaanxi Province, Natural Science Foundation of Shaanxi Province.
Abstract (Originalsprache)
Chemotherapy is widely used for cancer therapy but with unsatisfied efficacy, mainly due to the inefficient delivery of anticancer agents. Among the critical “five steps” drug delivery process, internalization into tumor cells and intracellular drug release are two important steps for the overall therapeutic efficiency. Strategy based on active targeting or TME‐responsive is developed individually to improve therapeutic efficiency, but with limited improvement. However, the combination of these two strategies could potentially augment the drug delivery efficiency and therapeutic efficiency, consequently. Therefore, this work constructs a library of stimuli‐responsive aptamer‐drug conjugates (srApDCs), as “dual‐targeted” strategy for cancer treatment that enables targeted drug delivery and controlled drug release. Specifically, this work uses different stimuli‐responsive linkers to conjugate a tumor‐targeting aptamer (i.e., AS1411) with drugs, forming the library of srApDCs for targeted cancer treatment. This design hypothesis is validated by the experimental data, which indicated that the aptamer could selectively enhance uptake of the srApDCs and the linkers could be cleaved by pathological cues in the TME to release the drug payload, leading to a significant enhancement of therapeutic efficacy. These results underscore the potential of the approach, providing a promising methodology for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory of Biomedical Information Engineering of Ministry of Education, Xi'an Jiaotong University, Xi'an, 710049, P. R. China.
- Bioinspired Engineering and Biomechanics Center (BEBC), Xi'an Jiaotong University, Xi'an, 710049, P. R. China.
- First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, 710049, P. R. China.
ORCID-Profile: Hui Guo
Förderung
- National Natural Science Foundation of China
- "SanQin Scholar" Innovation Team of Shaanxi Province
- Natural Science Foundation of Shaanxi Province
- State Key Laboratory of Engines
- Tianjin University
Zitieren
APA
Zhu, S., Gao, H., Li, W., He, X., Jiang, P., Xu, F., Jin, G., & Guo, H. (2024). Stimuli‐Responsive Aptamer‐Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release. Advanced Healthcare Materials, 13(23). https://doi.org/10.1002/adhm.202401020
Vancouver
Zhu S, Gao H, Li W, He X, Jiang P, Xu F, et al. Stimuli‐Responsive Aptamer‐Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release. Advanced Healthcare Materials. 2024;13(23). doi:10.1002/adhm.202401020
BibTeX
@article{Zhu2024,
author = {Zhu, Shanshan and Gao, Huan and Li, Wenyuan and He, Xiaocong and Jiang, Panpan and Xu, Feng and Jin, Guorui and Guo, Hui},
title = {Stimuli‐Responsive Aptamer‐Drug Conjugates for Targeted Drug Delivery and Controlled Drug Release},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {23},
doi = {10.1002/adhm.202401020}
}
EUVIMED